ITGAM and neoplasm: We further explored the anti-MDSCs potential of CTLA4-T cells, both granulocytic MDSCs (G-MDSCs, CD11b+Ly6G+) and monocytic MDSCs (M-MDSCs, CD11b+Ly6C+) were decreased within tumor tissues following CTLA4-T cells administration (Figure 4A).